Poland
· Delayed Price · Currency is PLN Read-Gene Statistics
Total Valuation
Read-Gene has a market cap or net worth of PLN 52.82 million. The enterprise value is 54.62 million.
| Market Cap | 52.82M |
| Enterprise Value | 54.62M |
Important Dates
The last earnings date was Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Read-Gene has 11.79 million shares outstanding.
| Current Share Class | 1.49M |
| Shares Outstanding | 11.79M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.16% |
| Owned by Institutions (%) | n/a |
| Float | 1.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.64 |
| PB Ratio | 15.77 |
| P/TBV Ratio | 15.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 67.94 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -92.41 |
| EV / Sales | 3.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.20, with a Debt / Equity ratio of 2.36.
| Current Ratio | 7.20 |
| Quick Ratio | 7.19 |
| Debt / Equity | 2.36 |
| Debt / EBITDA | 108.80 |
| Debt / FCF | n/a |
| Interest Coverage | -1.20 |
Financial Efficiency
Return on equity (ROE) is -17.19% and return on invested capital (ROIC) is -2.35%.
| Return on Equity (ROE) | -17.19% |
| Return on Assets (ROA) | -1.75% |
| Return on Invested Capital (ROIC) | -2.35% |
| Return on Capital Employed (ROCE) | -2.98% |
| Revenue Per Employee | 805,258 |
| Profits Per Employee | -32,836 |
| Employee Count | 22 |
| Asset Turnover | 1.02 |
| Inventory Turnover | 14.24 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.77% in the last 52 weeks. The beta is 0.68, so Read-Gene's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | -14.77% |
| 50-Day Moving Average | 4.36 |
| 200-Day Moving Average | 4.90 |
| Relative Strength Index (RSI) | 57.21 |
| Average Volume (20 Days) | 267 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Read-Gene had revenue of PLN 14.49 million and -591,039 in losses. Loss per share was -0.05.
| Revenue | 14.49M |
| Gross Profit | 13.52M |
| Operating Income | -395,841 |
| Pretax Income | -591,039 |
| Net Income | -591,039 |
| EBITDA | 72,687 |
| EBIT | -395,841 |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 6.11 million in cash and 7.91 million in debt, giving a net cash position of -1.80 million or -0.15 per share.
| Cash & Cash Equivalents | 6.11M |
| Total Debt | 7.91M |
| Net Cash | -1.80M |
| Net Cash Per Share | -0.15 |
| Equity (Book Value) | 3.35M |
| Book Value Per Share | 0.28 |
| Working Capital | 6.87M |
Cash Flow
| Operating Cash Flow | 777,492 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 93.25%, with operating and profit margins of -2.73% and -4.08%.
| Gross Margin | 93.25% |
| Operating Margin | -2.73% |
| Pretax Margin | -4.08% |
| Profit Margin | -4.08% |
| EBITDA Margin | 0.50% |
| EBIT Margin | -2.73% |
| FCF Margin | n/a |
Dividends & Yields
Read-Gene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -1.12% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Read-Gene has an Altman Z-Score of 4.45.
| Altman Z-Score | 4.45 |
| Piotroski F-Score | n/a |